|
業務類別
|
Biotechnology |
|
業務概覽
|
Janux Therapeutics Inc is a clinical-stage biopharmaceutical company developing tumor-activated immunotherapies for cancer. The proprietary technology of the company has enabled the development of distinct bispecific platforms: Tumor Activated T Cell Engagers (TRACTr), Tumor Activated Immunomodulators (TRACIr), and Adaptive Immune Response Modulator (ARM) platforms. The TRACTr platform produces T cell engagers (TCEs) with a tumor antigen-binding domain and a CD3 T cell binding domain, while the TRACIr platform produces bispecifics with a tumor antigen-binding domain and a costimulatory CD28 binding domain. |
| 公司地址
| 10955 Vista Sorrento Parkway, Suite 200, San Diego, CA, USA, 92130 |
| 電話號碼
| +1 858 751-4493 |
| 傳真號碼
| -- |
| 公司網頁
| https://www.januxrx.com |
| 員工數量
| 109 |
| Ms. Janeen Noel Doyle |
Chief Corporate and Business Development Officer and Interim Principal Accounting Officer |
美元 309.96K |
28/04/2026 |
| Mr. William Go |
Chief Medical Officer |
-- |
28/04/2026 |
| Dr. David Campbell, PhD |
Director, President and Chief Executive Officer |
美元 680.00K |
28/04/2026 |
| Mr. Charles M. Winter |
Chief Technical Officer |
-- |
28/04/2026 |
| Dr. Thomas DiRaimondo, PhD |
Chief Scientific Officer |
美元 478.00K |
28/04/2026 |
| Ms. Maria Dobek |
Vice President, Accounting and Principal Accounting Officer |
-- |
26/02/2026 |
|
|
| Dr. Ronald W. Barrett, PhD |
Independent Director |
28/04/2026 |
| Mr. Winston Kung, M.B.A. |
Independent Director |
28/04/2026 |
| Ms. Vickie L. Capps |
Independent Director |
28/04/2026 |
| Ms. Natasha A. Hernday |
Independent Director |
28/04/2026 |
| Dr. Sheila Gujrathi, M.D. |
Independent Director |
28/04/2026 |
| Dr. David Campbell, PhD |
Director, President and Chief Executive Officer |
28/04/2026 |
| Dr. Jake Simson, PhD |
Independent Director |
28/04/2026 |
| Ms. Alana B. McNulty |
Independent Director |
28/04/2026 |
|
|
|
|
